Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry

Author(s): Sashi Nadanaciva and Yvonne Will

Affiliation: Compound Safety Prediction, Pfizer Global R, Eastern Point Rd, Groton CT, 06340, USA.


Drug-induced mitochondrial dysfunction is a contributor to both late-stage compound attrition and post-market drug withdrawals. This review outlines the mechanisms which lead to drug-induced mitochondrial dysfunction and discusses the tremendous advances that have been made in the development of in vitro methods to identify mitochondrial impairment. Potentially useful animal models and in vivo methods to detect drug-induced mitochondrial impairment are also discussed.

Keywords: Mitochondrial dysfunction, oxidative phosphorylation, organ toxicity, mitochondrial diseases, drug safety, bioenergetics, mutation, metabolomics, dyslipidemia, NSAID, water, synthesis, organic

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [774 - 782]
Pages: 9
DOI: 10.2174/138945011795528985